Prognostic and predictive value of tumor in early breast cancer

被引：53

作者：

Criscitiello, Carmen ^{[1
]}

Esposito, Angela ^{[1
]}

Trapani, Dario ^{[1
]}

Curigliano, Giuseppe ^{[1
]}

机构：

[1] Ist Europeo Oncol, Via Ripamonti 435, I-20141 Milan, Italy

来源：

CANCER TREATMENT REVIEWS | 2016年 / 50卷

关键词：

Breast cancer; Tumor infiltrating lymphocytes; Biomarker; INFILTRATING LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; FREE SURVIVAL; TRASTUZUMAB; TRIAL;

D O I：

10.1016/j.ctrv.2016.09.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is well recognized that the immune system plays an essential role in tumor defense. The presence of tumor-infiltrating lymphocytes reflects an individual immunological response. In early breast cancer, the presence of TILs is associated with a more favorable outcome and response to therapy. In this review, we describe how TILs are assessed. Also, we discuss their role as prognostic and predictive biomarker in the neoadjuvant and adjuvant settings as well as in residual disease. Moreover, we discuss the possible implementation of TILs in daily clinical practice as well as in future clinical trials in order to fine tune prognosis and improve treatments. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：205 / 207

页数：3

共 22 条

[21] LYMPHORETICULAR INFILTRATION IN HUMAN TUMORS - PROGNOSTIC AND BIOLOGICAL IMPLICATIONS - REVIEW [J].

UNDERWOOD, JCE .

BRITISH JOURNAL OF CANCER, 1974, 30 (06) :538-548

[22] Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy [J].

Verma, S. ;

DeMichele, A. M. ;

Loi, S. ;

Ro, J. ;

Colleoni, M. ;

Iwata, H. ;

Harbeck, N. ;

Stearns, V. ;

Cristofanilli, M. ;

Bartlett, C. Huang ;

Schnell, P. ;

Zhang, K. ;

Thiele, A. ;

Turner, N. C. ;

Rugo, H. S. .

CANCER RESEARCH, 2016, 76

← 1 2 3 →